West Orange, NJ, United States of America

Theodros Asberom

This inventor holds 22 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Gamma Secretase Inhibitors. Top assignees: Schering Corporation, Merck Sharp + Dohme Corp., Pharacopeia Drug Discovery, Inc.. Active years: 1994-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Theodros Asberom. Retrieved from https://idiyas.com/inventor/theodros-asberom

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 2)

% Patents Active = 68.2

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 7.9

ph-index = 9

Forward Citations = 431(Granted Patents)

Location History:

Morris Plains, NJ (US) (1994)
West Orange, NJ (US) (1999 - 2015)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 1

Pharacopeia Drug Discovery, Inc.

patent

4. 1 out of 834,708

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2015

Loading Chart...

Areas of Expertise:

Gamma Secretase Inhibitors

Muscarinic Antagonists

Phosphodiesterase V Inhibitors

Thrombin Receptor Antagonists

2-Spiro-Substituted Iminothiazines

Compositions

Memory Loss Treatment

Polycyclic Guanine Derivatives

Benzensulfonyl-Chromane

Thiochromane

Tetrahydronaphthalene

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9181236 - 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use (2015-11-10),

2. 8759337 - Gamma secretase modulators (2014-06-24),

3. 8618123 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2013-12-31),

4. 8569521 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2013-10-29),

5. 8487099 - Gamma secretase modulators (2013-07-16),

6. 8357682 - Gamma secretase modulators (2013-01-22),

7. 8067621 - Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors (2011-11-29),

8. 7256186 - Gamma secretase inhibitors (2007-08-14),

9. 7208602 - Gamma secretase inhibitors (2007-04-24),

10. 7122675 - Gamma secretase inhibitors (2006-10-17),

11. 6969719 - Polycyclic guanine phosphodiesterase V inhibitors (2005-11-29),

12. 6943171 - Polycyclic guanine derivative phosphodiesterase V inhibitors (2005-09-13),

13. 6498168 - Muscarinic antagonists (2002-12-24),

14. 6326380 - Thrombin receptor antagonists (2001-12-04),

15. 6288068 - Muscarinic antagonists (2001-09-11),

Title: Theodros Asberom: Innovator in Pharmaceuticals

Introduction

Theodros Asberom, located in West Orange, NJ, is a prominent inventor known for his significant contributions to the pharmaceutical field. With a remarkable portfolio of 22 patents, Asberom has established himself as a leading patent holder in the development of innovative therapeutic compounds.

Latest Patents

Among his latest patents are two notable inventions: the 2-spiro-substituted iminothiazines and their mono-and dioxides as β-secretase inhibitors, and novel compounds that act as modulators of gamma secretase. The first invention elaborates on certain iminothiazine dioxide compounds, including those represented by Formula (I). These compounds are crucial in the ongoing search for effective treatments. The second patent covers methods of modulating gamma secretase activity and details how these compounds can be used in treating Alzheimer’s Disease, showcasing their potential in combating neurological disorders.

Career Highlights

Theodros Asberom has worked with renowned pharmaceutical companies such as Schering Corporation and Merck Sharp & Dohme Corporation. His experience in these established firms highlights his expertise and commitment to advancing medicinal chemistry and therapeutic intervention strategies.

Collaborations

Throughout his career, Asberom has collaborated with notable professionals in the field, including John W. Clader and Samuel Chackalamannil. These collaborations have contributed to his success in developing innovative solutions in drug design and discovery.

Conclusion

Theodros Asberom exemplifies the spirit of innovation within the pharmaceutical industry. With his extensive patent portfolio and collaborations with industry leaders, he continues to play a pivotal role in the advancement of medicinal therapies, making a significant impact on healthcare and the treatment of diseases like Alzheimer’s.

Profile summary based on public USPTO records.